MedAssets Stock Rating Reaffirmed by Sterne Agee (MDAS)
MedAssets (NASDAQ:MDAS)‘s stock had its “top pick” rating reiterated by stock analysts at Sterne Agee in a report issued on Monday, StockRatingsNetwork reports. They currently have a $30.00 price target on the stock. Sterne Agee’s price objective points to a potential upside of 22.50% from the stock’s previous close.
Shares of MedAssets (NASDAQ:MDAS) opened at 24.49 on Monday. MedAssets has a 1-year low of $15.40 and a 1-year high of $24.52. The stock has a 50-day moving average of $23.14 and a 200-day moving average of $19.62. The company has a market cap of $1.499 billion and a P/E ratio of 365.52.
MedAssets (NASDAQ:MDAS) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.26 by $0.04. The company had revenue of $170.70 million for the quarter, compared to the consensus estimate of $167.64 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. Analysts expect that MedAssets will post $1.31 EPS for the current fiscal year.
MDAS has been the subject of a number of other recent research reports. Analysts at Lazard Capital Markets downgraded shares of MedAssets (NASDAQ:MDAS) from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Separately, analysts at Zacks downgraded shares of MedAssets (NASDAQ:MDAS) from an “outperform” rating to a “neutral” rating in a research note to investors on Monday, August 19th. They now have a $25.80 price target on the stock. Finally, analysts at KeyCorp initiated coverage on shares of MedAssets (NASDAQ:MDAS) in a research note to investors on Tuesday, August 13th. They set a “hold” rating on the stock.
Four investment analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock. MedAssets presently has a consensus rating of “Buy” and an average target price of $26.47.
In other MedAssets news, CAO Lance M. Culbreth unloaded 4,000 shares of MedAssets stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $24.23, for a total value of $96,920.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.